Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 85 | 4,414 | 48% |
| 2020 | 68 | 4,155 | 50% |
| 2021 | 73 | 4,177 | 52% |
| 2022 | 69 | 4,067 | 53% |
| 2023 | 63 | 4,218 | 55% |
| 2024 | 77 | 3,603 | 56% |
| 2025 from claims | – | 3,996 3,668–4,228 | 56% |
| 2026 forecast | – | 4,068 3,579–4,694 | 56% |
| 2027 forecast | – | 4,119 3,521–4,909 | 56% |
| 2028 forecast | – | 4,170 3,480–5,107 | 56% |
| 2029 forecast | – | 4,222 3,449–5,295 | 57% |
| 2030 forecast | – | 4,275 3,425–5,478 | 57% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 28% of the cases CMS names in California; 54 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 83% inpatient hospital, 17% hospital outpatient. The share outside the hospital has moved −3 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 36 | 1,337+2.4%/yr | +2.4%/yr | 1.7 | 6% | 1,730 in 2030+4.4%/yr |
| Colorado | 24 | 1,147−1.6%/yr | −1.6%/yr | 2.3 | 1% | 1,280 in 2030+1.9%/yr |
| Washington | 12 | 886−6.9%/yr | −6.9%/yr | 1.1 | 11% | 890 in 20300%/yr |
| Oregon | 11 | 615−5.6%/yr | −5.6%/yr | 1.4 | 25% | 690 in 2030+2%/yr |
| Utah | 9 | 439−3.4%/yr | −3.4%/yr | 1.9 | 17% | 560 in 2030+4.1%/yr |
| Nevada | 3 | 378−6.4%/yr | −6.4%/yr | 1.3 | 0% | 370 in 2030−0.3%/yr |
| Idaho | 8 | 341−3.9%/yr | −3.9%/yr | 1.6 | 0% | 450 in 2030+4.8%/yr |
| Montana | 4 | 238−0.9%/yr | −0.9%/yr | 1.2 | 0% | 270 in 2030+2.1%/yr |
| Alaska | 5 | 221+8.1%/yr | +8.1%/yr | 1.8 | 0% | 400 in 2030+10%/yr |
| New Mexico | 2 | 123−6.5%/yr | −6.5%/yr | 0.5 | 0% | 250 in 2030+13%/yr |
| Wyoming | 2 | 111−8.1%/yr | −8.1%/yr | 1.0 | 0% | 160 in 2030+6.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 219 | 9,586−3.4%/yr | −3.4%/yr | 2.80.8× | 7% | 10,100 in 2030+0.8%/yr |
| Lumbar fusion | 199 | 8,753−1%/yr | −1%/yr | 2.50.8× | 2% | 9,020 in 2030+0.5%/yr |
| Kyphoplasty & vertebroplasty | 23 | 2,826−4.2%/yr | −4.2%/yr | 0.80.8× | 27% | 3,540 in 2030+3.8%/yr |
| SI joint fusion | 23 | 583+5.4%/yr | +5.4%/yr | 0.20.5× | 32% | 500 in 2030−2.5%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Medtronic leads with 35% of company spending on these surgeons in 2025, −17 pts on 2024.
In 2025, 20 companies reported engagement with California’s surgeons worth $1.3M in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.